Ranbaxy has posted sales of Rs 3.7 bn (up 24.4% YoY) and a net profit of Rs 427 mn (up 16% YoY) for the second quarter ended 30th June 1999. Ranbaxy is India's largest pharmaceutical company ranking 2nd behind Glaxo in the domestic market. It is the market leader in the antibiotic and therapeutic segments and also has significant presence in export markets.
The operating profit of the company jumped 26.5% to Rs 782 mn. While the company has been able to improve overall efficiency (Total expenditure moved up only 23.6% as against the 24.4% jump in sales), net profit margin declined to 11.5% (12.4%). The company has posted a 34% jump in export turnover vis a vis the 17% rise in domestic turnover.
The company has partially recovered from the decline in sale growth it suffered after the Russian economy went into a tailspin. The sustained recovery in international markets is likely to boost revenue growth at Ranbaxy, which derives a large part of its total income from international markets.
Market View:
The stock has been rated as a 'SELL' mainly due to the rich valuations enjoyed by the company.
Sorry! There are no related views on news for this company/sector.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More
Equitymaster requests your view! Post a comment on "Ranbaxy: Recovering from the Russian crisis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!